Drug Profile
BIIB 028
Alternative Names: BIIB028; CNF-3647Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Biogen
- Class Antineoplastics; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 17 Mar 2011 Biogen Idec completes enrolment in its phase I trial for Solid tumours in USA (NCT00725933)
- 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec